Abstract
Intraperitoneal chemotherapy has been described as a therapeutic option in the management of a variety of malignancies that occur primarily in a locoregional manner [1]. Potential benefits of this technique may occur in tumors principally confined to the peritoneal cavity (gastrointestinal malignancies and ovarian carcinoma) [2,3]. Theoretically, the use of intraperitoneal drug could eliminate local tumor spread as a mechanism of cancer recurrence both in the abdomen and in the pelvis.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Spratt JS, Edwards M, Kubota T, Lindberg R, Tseng MT. Peritoneal carcinomatosis: Anatomy, physiology, diagnosis and management. Curr Prol Cancer 1986;10:553–584.
Sugarbaker PH, Cunliffe W, Belliveau J, et al. Rationale for early postoperative intraperitoneal chemotherapy as a surgical adjuvant for gastrointestinal malignancy. Reg Cancer Treat 1989;1:66–79.
Markman M, Howell SB, Lucas WE, Pfeifle CE, Green MR. Combination intraperitoneal chemotherapy with cisplatin, cytarabine, doxorubicin for refractoy ovarian carcinoma and other malignancies principally confiend to the peritoneal cavity. J Clin Oncol 1984;2: 1321–1325.
Jacquet P, Vidal-Jove J, Zhu B, Sugarbaker PH. Peritoneal carcinomatosis from gastrointestinal malignacy: Natural history and new prospects for management. Acta Chir Belg 1994;94:191–197.
Sugarbaker PH. Cytoreductive approach to peritoneal carcinomatosis: Peritonectomy and intraperitoneal chemotherapy. In Postgraduate Advances in Colorectal Surgery. Forum Medicum, 1991, II-X.
Esperanda MJ, Collins DL. Peritoneal dialysis efficiency in relaion to body weight. J Pediatr Sur 1966;1:162–169.
Pfeiffer CJ, Pfeiffer DC, Misra HP. Enteric serosal surface in the piglet. A scanning and transmission electron microscopic study of the mesothelium. J Submicrosc Cytol 1987; 19: 237–246.
Waiters WB, Buck RC. Scanning electron microscopy of mesothelial regeneration in the rat. Lab Invest 1972;26:604–609.
Kruger S, Greve DW, Schueler FW. Absorption of fluid from peritoneal cavity. Arch Int Pharmacodyn Ther 1962;137:173–178.
Yoffey JM, Courtice FC. Lymphatics, Lymph and the Lymphomyeloid Complex. London: Academic Press, 1970;206–231.
Greenwalt D, Nakamura RM, diZerega G. Determination of pH and pKa in human peritoneal fluid. Curr Surg 1988;45:217–218.
Aune S. Transperitoneal exchange IV. The effect of transperitoneal fluid transport on the transfer of solutes. Scand J Gastroenterol 1970;5:241–252.
Torres IG, Litterest CL, Guarino AM. Transport of model compounds across the peritoneal menbrane in the rat. Pharmacology 1987;17:330–340.
Fedorko ME, Hirsch JG, Studies on transport of macromolecules and small particles across the mesothelial cells of the mouse omentum. I. Morphological aspects. Exp Cell Res 1971;69:113–127.
Lukas G, Brindle SD, Greengerd P. The route of absorption of intraperitoneally administered compounds. J Pharmacol Exp Ther 1971;178:562–566.
Rippe B, Stelin G. Peritoneal transport of water and solutes. Proceedings of Peritoneum and Peritoneal Access. Lund: Sweden, 1987, p 41.
Arnaud JP, Adolf M. Physiopathologie du péritoine. Péritonisation-drainage. In Encycl Med Chir Techniques chirurgicales, Appareil digestif. Paris: 1989(11);40070: 15.
Leak LV, Rahil K. Permeability of the diaphragmatic mesothelium:the ultrastructural basis for stromata. Am J Anat 1978;151:557–594.
Lill SR, Parsons RH, Buchac I. Permeability of the diaphragma nd fluid resorption from the peritoneal cavity in the rat. Gastroenterology 1979;76:997–1002.
Flessner ME, Fenstermacher JD, Blasberg RG, et al. Peritoneal absorption of macro-molecules studied by quantitative autoradiography. Am J Physiol 1985;248:26–32.
Sugarbaker PH, Cunliffe WJ, Belliveau J, de Cruijn EA, et al. Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer. Semin Oncol 1989;16:83–97.
Gross ML, Somani P, Ribner BS, Raeader R, et al. Ceftizoxime elimination kinetics in continuous ambulatory peritoneal dialysis. Clin Pharmacol Ther 1983;34:673–680.
Keller E, Reetze, P, Schollmeyer P. Drug therapy in patients undergoing continuous ambulatory peritoneal dialysis. Clin Pharmacokinet 1900;18:104–117.
Dedrick RL. Theoretical and experimental bases of intraperitoneal chemotherapy. Semin Oncol 1985;12:1–6.
Flessner MF, Dedrick RL, Schultz JS. A distributed model of peritoneal-plasma transport: Analysis of experimental data in the rat. Am J Physiol 1985;248:F413-F424.
Rubin J, Jones Q, Planch A, Bower JD. The minimal importance of the hollow viscera to peritoneal transport during peritoneal dialysis in the rat. Am Soc Artif Intern Organs Transact 1988;34:912–915.
Sugarbaker PH, Klecker RW, Gianola FJ, Speyer JL. Prolonged treatment schedules with intraperitoneal 5-fluorouracil diminish the loco-regional naure of drug distribution. Am J Clin Oncol 1986;9:1–7.
Sugarbaker PH, Stuart OA, Vidal-Jove J, Pessagno AM, DeBruijn EA. Studies of the peritonea-plasma barrier after systemic mitomycin C administration. Reg Cancer Treat 1993;4:188–194.
Maher JF. Physiology of the peritoneum. Implications for peritoneal dialysis. Med Clin North Am 1990;74(4):985–996.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Kluwer Academic Publishers, Boston
About this chapter
Cite this chapter
Jacquet, P., Sugarbaker, P.H. (1996). Peritoneal-plasma barrier. In: Sugarbaker, P.H. (eds) Peritoneal Carcinomatosis: Principles of Management. Cancer Treatment and Research, vol 82. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-1247-5_4
Download citation
DOI: https://doi.org/10.1007/978-1-4613-1247-5_4
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-8531-1
Online ISBN: 978-1-4613-1247-5
eBook Packages: Springer Book Archive